Apixaban vs. Aspirin for Subclinical Atrial Fibrillation

Crawford, Michael H. MD

Editor

Clinical Cardiology Alert 43(1):p 3-4, January 2024.

SYNOPSIS: A randomized controlled trial of apixaban vs. low-dose aspirin therapy for subclinical atrial fibrillation detected by implanted electrophysiologic devices showed that apixaban is associated with fewer strokes, but more major bleeding episodes compared to aspirin.

SOURCE: Healey JS, Lopes RD, Granger CB, et al. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med 2023; Nov 12. doi: 10.1056/NEJMoa2310234. [Online ahead of print]. Presented at the American Heart Association Annual Scientific Sessions, Nov. 11-13, 2023.